The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f ...

Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...

Weight management platform Found is today launching oral semaglutide dissolvable tablets for individuals looking for ...

The Food and Drug Administration on Friday approved Eli Lilly’s anti-obesity drug Zepbound as the first prescription medicine for obstructive sleep apnea, marking a major shift in the treatment of the ...

The U.S. Food and Drug Administration (FDA) has granted approval for Zepbound, a weight-loss medication, to treat moderate to severe obstructive sleep apnea (OSA) in individuals with obesity.

For Floridians, 2024 was a year of weight loss and emerging revelations about anti-obesity medications.

The Food and Drug Administration on Friday approved Eli Lilly’s anti-obesity drug Zepbound as the first prescription medicine for obstructive sleep apnea, marking a major shift in the treatment ...

A 2024 study in the American Journal of Managed Care found that patients’ health care costs declined by $7,502 after they began treatment with the anti-obesity drug semaglutide. Importantly ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.

The U.S. health regulator reminded compounders of the legal restrictions on making copies of FDA-approved drugs. Also Read: US Employer Health Costs To Rise In 2025 Fueled By Weight Loss ...